Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial
- 1 October 2009
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 54 (4), 647-652
- https://doi.org/10.1053/j.ajkd.2009.04.036
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective TherapyAmerican Journal of Kidney Diseases, 2008
- Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled TrialAmerican Journal of Kidney Diseases, 2008
- 1 ,25-dihydroxyvitamin D3 is a potent suppressor of interferon -mediated macrophage activationBlood, 2005
- 1,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized ratAmerican Journal of Physiology-Renal Physiology, 2004
- 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin systemJournal of Clinical Investigation, 2002
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- 1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell ActivationThe Journal of Immunology, 2000
- SPECIFIC HIGH-AFFINITY RECEPTORS FOR 1,25-DIHYDROXYVITAMIN D3IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS: PRESENCE IN MONOCYTES AND INDUCTION IN T LYMPHOCYTES FOLLOWING ACTIVATIONJournal of Clinical Endocrinology & Metabolism, 1983